IDH1 R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. IDH1 R132H point mutations are frequently seen in World Health Organization grade II and III gliomas and are believed to constitute an early step in tumorigenesis. IDH1 R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 R132H antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the R132H-mutated peptide. Diffuse staining of the fibrillary tumor matrix is also seen.
200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 1mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
FFPE prostate carcinoma with IDH1-R132H mutation stained with
FFPE human glioblastoma with IDH1-R132H mutation stained with IDH1-R132H Recombinant Rabbit Monoclonal Antibody (IDH1/6806R). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.
FFPE prostate carcinoma with IDH1-R132H mutation stained with IDH1-R132H Recombinant Rabbit Monoclonal Antibody (IDH1/6806R).
IHC analysis of formalin-fixed, paraffin-embedded human cerebellum. Negative tissue control using IDH1/6806R at 2ug/ml in PBS for 30min RT. HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.
Western Blot Analysis of Human Liver tissue lysate using IDH1 Recombinant Rabbit Monoclonal Antibody (IDH1/6806R).
Western Blot Analysis of Liver tissue lysates of different species using IDH1 Recombinant Rabbit Monoclonal Antibody (IDH1/6806R).
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
